Cytiva Webinar：細胞遺伝子治療薬におけるプラットフォーム開発

細胞遺伝子治療薬におけるプラットフォーム開発

細胞遺伝子治療薬製造のための堅牢なプロセスを開発する際、課題をよりよく理解したいとお考えですか？社内のプロセス開発機能、重要なアウトソーシングの決定、問題解決、または次のマイルストーンにすばやく到達するための新しいソリューションの発見が大変重要になってきます。

本Webinarでは、細胞遺伝子治療薬製造の市場動向について説明したのち、以下トピックスをご紹介していきます。

Custom media development for C＆GT

Top-down vs. bottom-up approach
Mass spectrometry and multivariate statistical analysis
DoE formulations screening
Animal component free case study

Cell line Development for Viral Vector Production

Cell line screening
Suspension adaptation
Transfer vector integration techniques
Viral Titering

Webinar OUTLINE

Watch on-demand Recorded 2021年11月11日

Philip G. Vanek, Ph.D. Partner at Gamma Biosciences　MORE INFO

Gary M. Pigeau, Ph.D. Director, Centre for Advanced Therapeutic Cell Technologies　MORE INFO

Steven Loo-Yong-Kee MEng Development Engineer/Scientist BRIDGE at CCRM　MORE INFO

英語（日本語字幕付き）

※本動画は2020年12月8日にCytiva Festival Week 2020で放映されたウェビナーに、日本語字幕をつけたものです。

※以下よりご登録いただきますとWebinar On-Demandへのリンクをメールにてお送りさせていただきます。
※SafariやFireFox™でご覧いただいている場合、フォームが表示されないケースがございます。その際はChrome等のブラウザでお試しください。

Philip G. Vanek, Ph.D.

Partner at Gamma Biosciences

Biography

Phil is a passionate advocate for regenerative medicine and the role it will play in treating diseases as global healthcare systems transition to precision health models. An entrepreneurial and strategic international business leader, Phil has led marketing, business development, and innovation in start-up and established biotechnology companies. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center. Phil held leadership positions at Life Technologies, Atto Bioscience, BD Biosciences, and Lonza Bioscience before joining GE Healthcare. His business and academic experiences give him a unique perspective of the global opportunities and challenges of the biotechnology industry.

Gary M. Pigeau, Ph.D.

Director
Centre for Advanced Therapeutic Cell Technologies

Biography

Centre for Advanced Therapeutic Cell Technologies Gary Pigeau joined GE Healthcare in 2016 and is Director of the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in Toronto, Ontario. He received his Ph.D. in Biotechnology from Brock University and completed a postdoctoral fellowship at the University of Alberta, with a visiting scientist appointment at the University of Oxford. One of Gary’s first projects at CATCT was design oversight of the custom media development infrastructure. The CATCT collaboration has a focus on biology support for New Product Introductions, internal technology development projects and contract process development services in cell and gene therapy.

Steven Loo-Yong-Kee

MEng Development Engineer/Scientist
BRIDGE at CCRM

Biography

Steven is a senior development associate at CCRM focusing on improving manufacturing and accelerating commercialization of viral vectors and immunotherapies. His experience includes developing and optimizing a semi-automated closed CAR-T manufacturing process utilizing commercially available cGMP media, reagents and equipment, as well as evaluating serum-free suspension cell lines and transient transfection methods for scalable for LV and AAV production.

Cytiva Webinar

細胞遺伝子治療薬におけるプラットフォーム開発

CONTENTS

Webinar OUTLINE

自動的に転送されない場合は、こちらをクリックしてください。

Philip G. Vanek, Ph.D.

Biography

Gary M. Pigeau, Ph.D.

Biography

Steven Loo-Yong-Kee

Biography